

Abklärung und Therapie der männlichen Unfruchtbarkeit

PD Dr. Markus Margreiter



Unfruchtbarkeit – Übersicht



- Betrifft ~ 15% aller Paare
- 30% nur männlicher Faktor
- 30% Kombination männlicher/weiblicher Faktoren
- Azoospermie
 - 1-2% gesamten männlichen Bevölkerung
 - 10% Männern mit unerfülltem Kinderwunsch
- Ausgaben für KiWu bei männlichen Faktor 18 Mrd. \$/Jahr


Recommendations	Strength rating
Investigate both partners simultaneously , to categorise infertility.	Strong
Include the fertility status of the female partner in the diagnosis and management of male sub-fertility because this might determine the final outcome.	Strong
Examine all men diagnosed with fertility problems , including men with abnormal semen parameters for urogenital abnormalities .	Strong

Diagnosis	Unselected patients (n = 12,945)	Azoospermic patients (n = 1,446)
All	100%	11.2%
Infertility of known (possible) cause	42.6%	42.6%
Maldescended testes	8.4	17.2
Varicocele	14.8	10.9
Sperm autoantibodies	3.9	-
Testicular tumour	1.2	2.8
Others	5.0	1.2
Idiopathic infertility	30.0	13.3
Hypogonadism	10.1	16.4
Klinefelter's syndrome (47, XXY)	2.6	13.7

Abklärung des Mannes

3 Klinische Eckpfeiler:

- Krankengeschichte
- Körperliche Untersuchung
- Labortests: Samenanalyse und Hormone
- (Spezialisierte Tests)



Anamnese

- Unfruchtbarkeit
 - Dauer, vorherige Kinder, weiblicher Faktor
- Hormonelle Symptome
 - Gynäkomastie, Galaktorrhoe, Körperbehaarung, Libido, Pubertätsalter
- Angeboren
 - Kryptorchismus, Torsion, Trauma, Familiengeschichte der Unfruchtbarkeit



Sexuelle Anamnese



- Häufigkeit des Verkehrs
- Häufigkeit der Ejakulation
- Schmerzen bei der Ejakulation
- Verwendung von Gleitmitteln
- Timing zum Eisprung

Vorerkrankungen

- Infektiös
 - Geschlechtskrankheiten, Mumps
- Operationen
 - Vasektomie, Leistenbruch, Hodenoperationen, RPLND
- Gonadotoxinexposition
 - Chemo, Radiatio, Medikamente
- Andere
 - Anosmie, visuelle Veränderungen, Kopfschmerzen





Körperliche Untersuchung

- Allgemeines
 - Sekundäre Geschlechtsmerkmale
- Brust
 - Gynäkomastie
- Uro-Genital
 - Vorhandensein des Vas deferens, Hodengröße, Penisanomalien, Varikozelen, Prostata (Prostatitis)




Hodenultrascall

- Ausschluss:
 - Hodentumor
 - Mikrolithiasis
- Bestimmung:
 - Hodenvolumen
- Beschreibung:
 - Veränderungen Nebenhoden



Samenanalyse

- Mind. 3-5 Tage Karenz (kein Samenerguss (GV und/oder Masturbation))
- Wenn pathologisch mind. 2 Analysen (Abstand 4 Wochen)
- Probe nicht älter als 30 Minuten



WHO 2010

Parameter	Lower reference limit (range)
Semen volume (mL)	1.5 (1.4-1.7)
Total sperm number (10^6 /ejaculate)	39 (33-46)
Sperm concentration (10^6 /mL)	15 (12-16)
Total motility (PR + NP)	40 (38-42)
Progressive motility (PR, %)	32 (31-34)
Vitality (live spermatozoa, %)	58 (55-63)
Sperm morphology (normal forms, %)	4 (3.0-4.0)
Other consensus threshold values	
pH	> 7.2
Peroxidase-positive leukocytes (10^6 /mL)	< 1.0
Optional investigations	
MAR test (motile spermatozoa with bound particles, %)	< 50
Immunobead test (motile spermatozoa with bound beads, %)	< 50
Seminal zinc (μ mol/ejaculate)	> 2.4
Seminal fructose (μ mol/ejaculate)	> 13
Seminal neutral glucosidase (mU/ejaculate)	< 20



WHO Änderungen

WHO	1987	1992	1999	2010		
	normal	normal	Ref.	threshold	range (%)	
				5	50	95
Ejaculate volume (ml)	2.0	2.0	2.0	1.5	3.7	6.8
Total sperm number	40	40	40	39	255	802
Concentration (M/ml)	20	20	20	15	73	213
Progr. Motility (%)	50	50	50	32	55	72
Vitality (%)	50	75	75	58	79	91
Sperm Morphology (%)	50	30	(15)	4	11	21



The Disappearing Sperms: Analysis of Reports Published Between 1980 and 2015

Spermienkonzentration	1985 - 2015
Verbesserung	3,6 %
Unverändert	15,9 %
Verschlechterung	80,4 %



Endokrine Abklärung

- Indikationen
 - Niedrige Spermienkonzentration (< 10 Mio/ml)
 - Beeinträchtigte sexuelle Funktion
 - Anderer HW auf eine Endokrinopathie
- Beginnen mit FSH & Total Testosteron
 - Bei Anomalie: LH, Prolaktin, TSH
 - Spezielle Diagnostik

Normales FSH garantiert keine intakte Spermatogenese, jedoch deutet ein abnormales oder hohes Normal auf eine Abnormalität der Spermatogenese hin



Bekannte genetische Ursachen für männliche Infertilität

Chromosomenanomalie

- Numerische Abnormalitäten:
 - Klinefelter-Syndrom und Varianten (47 XXY; etwa 15% Mosaik (46XY/47XXY))
- Strukturelle Abnormalitäten:
 - X-chromosomal
 - Kallmann-Syndrom
 - Partielles und komplettes Androgen-Insensitivitäts-Syndrom
 - Y-Chromosomal
 - AZF-Deletionen
 - Gr/gr-Deletion



Recommendations	<u>Strength rating</u>
Obtain standard karyotype analysis in all men with damaged spermatogenesis (spermatozoa < 10 million/mL) for diagnostic purposes.	<u>Strong</u>
Provide genetic counselling in all couples with a genetic abnormality found in clinical or genetic investigation and in patients who carry a (potential) inheritable disease.	<u>Strong</u>
For all men with Klinefelter's syndrome , provide long-term endocrine follow-up and appropriate medical treatment , if necessary.	<u>Strong</u>
Do not test for microdeletions in men with obstructive azoospermia (OA) since spermatogenesis should be normal.	<u>Strong</u>
Inform men with Yq microdeletion and their partners who wish to proceed with intracytoplasmic sperm injection (ICSI) that microdeletions will be passed to sons , but not to daughters.	<u>Strong</u>
In men with structural abnormalities of the vas deferens (unilateral or bilateral absence with no renal agenesis), test the man and his partner for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations .	<u>Strong</u>


Where is the threshold for genetic evaluation ?

- Normal genetic evaluation < 10 Mio/mL
- AZF deletions: < 5 Mio/mL

Now we do not have enough evidence for a clear cutoff !

Therapeutische Optionen bei andrologischer Sub/Infertilität

- Medikamentös
- Operativ
- Reproduktionsmedizinische Maßnahmen



Medical treatment of male infertility

Ali A. Dabaja, Peter N. Schlegel

Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA

Correspondence to: Peter N. Schlegel. Department of Urology, Weill Cornell Medical College, 525 E 68th street, New York, NY 10065, USA. Email: pnschleg@med.cornell.edu.




Table 1 Reviewed medical treatment of male infertility

Substance	Administration	Dosage and frequency	Current availability
GnRH	Subcutaneous infusion pump	25-200 ng/kg per pulse every 2 hours	Only in specialty centers or part of clinical trials
Human chorionic-gonadotropin (hCG)	Subcutaneous/intramuscular	1,500-3,000 IU 2 times/week	Available, FDA approved for treatment of infertility due to gonadotropin deficiency
Human menopausal gonadotropin (hMG)	Subcutaneous/intramuscular	75 IU 2-3 times/week	Available, FDA approved for treatment of infertility due to gonadotropin deficiency
Highly purified or recombinant human follicle-stimulating hormone (rhFSH)	Subcutaneous/intramuscular	100-150 IU 2-3 times/week	Available, FDA approved for treatment of infertility due to gonadotropin deficiency
Dopamine agonist	Oral	Cabergoline (0.5-1 mg twice weekly), bromocriptine (2.5-5.0 mg twice weekly)	FDA approval for treatment of hyperprolactinaemia
Aromatase inhibitors	Oral	Anastrozole 1 mg/day Letrozole 2.5 mg/day Testolactone	Off label use Off label use Not available in the USA
Selective estrogen receptor modulators (SERMs)	Oral	Clomiphene citrate titrate to 50 mg/day Tamoxifen 20 mg/day, toremifene 60 mg/day, raloxifene 60 mg/day	Off label use Off label use



Operativ

available at www.sciencedirect.com
journal homepage: www.europeanurology.com

eau
European Association of Urology



Surgery for Male Infertility

Peter N. Schlegel, Markus Margreiter*

Department of Urology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY, USA

- Orchidopexie (vor dem 1. Lebensjahr mit neo-adjuvanter Kryptokur-Therapie)
- TUR von Ejakulationskanälen (TURED)
- Varikozelen-Operation
- Refertilisierungs-OPs (Vaso-Vasostomie)
- Samenzellengewinnung



Varicocele

- 11,7% der erwachsenen Männer
- 25,4% der Männer mit abnormaler Samenanalyse
- Meta-Analyse: Samenverbesserung nach operativer Korrektur einer Varikokelektomie bei azoospermischen Männern vor TESE?
- Eine Varikokelektomie kann eine Schädigung der Spermien-DNA umkehren.
- Metaanalyse: Varikokelektomie kann die Ergebnisse von ART bei oligozoospermischen Männern verbessern

Argawal et al. Urology, 2007. 70: 532

[Shiraishi et al. J Urol. 2017 Feb;197\(2\):485-490](#)

Kroese et al. Cochrane Database Syst Rev, 2012


[Kirby et al. Fertil Steril, 2016. 106: 1338](#)

Treatment	Ref.	Recurrence/ Persistence %	Complication rates
Antegrade sclerotherapy	[130]	9	Complication rate 0.3-2.2%: testicular atrophy, scrotal haematoma, epididymitis, left-flank erythema.
Retrograde sclerotherapy	[131]	9.8	Adverse reaction to contrast medium, flank pain, persistent thrombophlebitis, vascular perforation.
Retrograde embolisation	[132, 133]	3.8-10	Pain due to thrombophlebitis, bleeding haematoma, infection, venous perforation, hydrocele, radiological complication (e.g., reaction to contrast media), misplacement or migration of coils, retroperitoneal haemorrhage, fibrosis, ureteric obstruction.
Open operation			
Scrotal operation		-	Testicular atrophy, arterial damage with risk of devascularisation and testicular gangrene, scrotal haematoma, post-operative hydrocele.
Inguinal approach	[134]	13.3	Possibility of missing out a branch of testicular vein.
High ligation	[135]	29	5-10% incidence of hydrocele (< 1%).
Microsurgical inguinal or subinguinal	[136, 137]	0.8-4	Post-operative hydrocele arterial injury, scrotal haematoma.
Laparoscopy	[138, 139]	3-7	Injury to testicular artery and lymph vessels; intestinal, vascular and nerve damage; pulmonary embolism; peritonitis; bleeding; post-operative pain in right shoulder (due to diaphragmatic stretching during pneumoperitoneum); pneumoscrotum; wound infection.

Recommendations	Strength rating
<p>Treat varicoceles in <u>adolescents</u> with ipsilateral reduction in testicular volume and evidence of progressive testicular dysfunction.</p>	<p>Weak</p>
<p>Do not treat varicoceles in infertile men who have normal semen analysis and in men with a subclinical varicocele.</p>	<p>Strong</p>
<p>Treat men with a clinical varicocele, oligozoospermia and otherwise unexplained infertility in the couple.</p>	<p>Weak</p>

Perkutane Epidymale Spermatozoen-Aspiration (PESA)

- **26 G
Tuberculi
n syringe**



*Image from Esteves SC, et al: Int Brazil J Urol 2011.


Testikuläre Spermatozoen Aspiration (TESA)

- 18-22 G
- Superior testicular pole




*Image from Esteves SC, et al: Int Brazil J Urol 2011.


Testikuläre Spermatozoen-Extraktionen (TESE)



Micro-TESE



Sertoli – Cell - Only



Hypospermatogenesis



Outcomes

Procedure	Anesthetic	Sperm Retrieval Rate	Yield
MESA	General	95-100%	Cryo in 98-100% 15-95 x 10 ⁶ 15-42% motility
PESA	Local	80-100%	Cryo 43-96% 10 ³ -10 ⁶
Testicular Fine Needle Aspiration	Local	52-100%	Cryo 38% 10 ⁵ -10 ⁶
Testicular Large Needle Aspiration	Local	98-100%	Cryo 100% 10 ⁵ -10 ⁶
Testicular Core Needle Biopsy	Local	82-100%	Cryo Sufficient 10 ⁵ -10 ⁶
TESE	General, Regional, Local	100%	Cryo Sufficient 10 ⁵ -10 ⁶
Microdissection TESE	General	100%	Cryo Sufficient 10 ⁵ -10 ⁶



Diagnostik und Therapie sollte



in Stufen erfolgen unter Berücksichtigung von

- Lebensalter
- Zeitraum des unerfüllt gebliebenen Kinderwunsches
- In Abhängigkeit von der Zeit des Kinderwunsches
- Vorbefunden

Die reproduktionsmedizinische Diagnostik und Therapie erfordert bei auffälligen Befunden

die Auswahl von Maßnahmen,

- die mit möglichst geringer Invasivität
- möglichst geringen Kosten und
- möglichst hoher Sicherheit

dem Paar zu einem gemeinsamen Kind verhelfen können

Fertilität als Marker für Männergesundheit



American Journal of Epidemiology

© The Author 2009. Published by the Johns Hopkins Bloomberg School of Public Health.

All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

Vol. 170, No. 5

DOI: 10.1093/aje/kwp168

Advance Access publication July 27, 2009

Original Contribution

Good Semen Quality and Life Expectancy: A Cohort Study of 43,277 Men

Tina Kold Jensen, Rune Jacobsen, Kaare Christensen, Niels Christian Nielsen, and Erik Bostofte

Initially submitted March 11, 2009; accepted for publication May 26, 2009.



Infertilität und PCa

Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study

Yahia Al-Jebari,¹ Angel Elenkov,^{1,2,3} Elin Wirestrand,¹ Indra Schütz,¹ Aleksander Giwercman,^{1,3}
Yvonne Lundberg Giwercman¹

Conclusions

- Men who achieved fatherhood through assisted reproduction techniques, particularly through ICSI, are at increased risk for early onset prostate cancer and thus constitute a risk group in which testing and careful long term follow-up for prostate cancer may be beneficial.



Vielen Dank für Ihre
Aufmerksamkeit!




Wichtige Rahmenaspekte der menschlichen Fortpflanzung:




- bei fertilen Paaren (<35 Jahren) und optimalem Timing des GV (12-36 h vor Ovulation) kommt es
 - pro Zyklus in maximal 20% und
 - pro Jahr in etwa 80 %
 - zu einer klinisch nachweisbaren Schwangerschaft
- diese Raten reduzieren sich bei gesunden (!) Frauen
 - zwischen 35- 40 Jahren um etwa 30-40 %
 - und ab > 40 Jahren um mehr als 75%




Hormoneller Regelkreis



Anatomie



Ursachen Männliche Unfruchtbarkeit



Diagnosis	Unselected patients (n = 12,945)	Azoospermic patients (n = 1,446)
<i>All</i>	100%	11.2%
<i>Infertility of known (possible) cause</i>	42.6%	42.6%
Maldescended testes	8.4	17.2
Varicocele	14.8	10.9
Sperm autoantibodies	3.9	-
Testicular tumour	1.2	2.8
Others	5.0	1.2
<i>Idiopathic infertility</i>	30.0	13.3
<i>Hypogonadism</i>	10.1	16.4
Klinefelter's syndrome (47, XXY)	2.6	13.7
XX male	0.1	0.6
Primary hypogonadism of unknown cause	2.3	0.8
Secondary (hypogonadotropic) hypogonadism	1.6	1.9
Kallmann syndrome	0.3	0.5
Idiopathic hypogonadotrophic hypogonadism	0.4	0.4
Residual after pituitary surgery	<0.1	0.3
Others	0.8	0.8
Late-onset hypogonadism	2.2	-
Constitutional delay of puberty	1.4	-
<i>General/systemic disease</i>	2.2	0.5
<i>Cryopreservation due to malignant disease</i>	7.8	12.5
Testicular tumour	5.0	4.3
Lymphoma	1.5	4.6



